A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

This study is testing a CAR-T cell therapy called GT801 — which uses a patient's own immune cells modified to attack cancer — in adults with blood cancers that have relapsed or stopped responding to treatment. The cancers targeted include certain types of leukemia, lymphoma, and a rare immune condition called autoimmune hemolytic anemia. **You may be eligible if...** - You are 18–75 years old with relapsed or refractory B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, B-cell non-Hodgkin lymphoma, or autoimmune hemolytic anemia - Your cancer has not responded to or came back after at least two prior treatments - Your cancer cells test positive for the CD19 protein (for blood cancers) - Your overall health allows for treatment (ECOG 0–1 for blood cancers) - Your expected survival is more than 12 weeks - Enough time has passed since your last cancer treatment **You may NOT be eligible if...** - Your cancer is a different type than those listed - You have had a prior stem cell transplant or CAR-T therapy involving certain targets - You have active brain involvement by the cancer - You have uncontrolled serious infections, heart problems, or organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.